Tandlægeselskabet Colosseumklinikken Østerport ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  5.5% 8.5% 4.9% 1.8% 3.4%  
Credit score (0-100)  43 29 43 71 53  
Credit rating  BBB BB BBB A BBB  
Credit limit (kDKK)  0.0 0.0 0.0 2.8 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  5,877 6,759 9,734 11,388 10,251  
EBITDA  45.3 75.5 1,460 1,929 1,051  
EBIT  -234 -322 541 1,059 171  
Pre-tax profit (PTP)  -336.4 -377.3 460.8 1,001.5 150.5  
Net earnings  -262.9 -353.9 460.8 799.6 -0.5  
Pre-tax profit without non-rec. items  -336 -377 461 1,001 150  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  1,264 3,195 2,792 2,310 1,469  
Shareholders equity total  -213 -567 -106 1,099 599  
Interest-bearing liabilities  2,120 2,777 2,884 0.0 0.0  
Balance sheet total (assets)  3,041 4,804 5,024 3,756 2,739  

Net Debt  1,026 1,927 1,747 -522 -110  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  5,877 6,759 9,734 11,388 10,251  
Gross profit growth  0.0% 15.0% 44.0% 17.0% -10.0%  
Employees  10 14 14 13 13  
Employee growth %  0.0% 40.0% 0.0% -7.1% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  3,041 4,804 5,024 3,756 2,739  
Balance sheet change%  0.0% 58.0% 4.6% -25.2% -27.1%  
Added value  45.3 75.5 1,459.5 1,977.9 1,051.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  985 1,533 -1,323 -1,351 -1,722  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 -2.0 1.0 2.0 3.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  -4.0% -4.8% 5.6% 9.3% 1.7%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -7.1% -7.3% 10.3% 23.8% 5.4%  
ROI %  -10.4% -11.8% 18.1% 46.6% 12.8%  
ROE %  -8.6% -9.0% 9.4% 26.1% -0.1%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  -6.5% -10.6% -2.1% 29.3% 22.3%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  2,266.3% 2,551.9% 119.7% -27.1% -10.5%  
Gearing %  -995.6% -489.9% -2,723.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  9.9% 2.6% 2.9% 4.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.5 0.3 0.4 0.6 0.9  
Current Ratio  0.5 0.4 0.5 0.6 1.0  
Cash and cash equivalent  1,093.3 849.6 1,137.4 522.2 110.4  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -1,485.9 -2,673.5 -2,517.0 -765.2 -46.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  5 5 104 152 81  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  5 5 104 148 81  
EBIT / employee  -23 -23 39 81 13  
Net earnings / employee  -26 -25 33 62 -0